source
- Biotech pay analysis: 12 execs with $35M+ M&A golden parachutesA dozen biotech executives took home nearly $1 billion worth of exit packages from selling their companies, an Endpoints News analysis found. The drug industry is undergoing a historic stretch of M…Endpoints · 1mo ago↗ source
- Ethyreal lands $101M to treat both Graves' and thyroid eye diseaseA biotech backed by Atlas Venture and Medicxi uncloaked on Wednesday morning to tackle the related autoimmune conditions Graves' disease and thyroid eye disease, and the startup plans to enter the…Endpoints · 1mo ago↗ source
- Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studySanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of t…